Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Radium-224 calcium carbonate microparticles (Radspherin) is an investigational, receptor-independent, alpha-emitting radiopharmaceutical designed for the local treatment of metastatic cancers in body cavities, particularly peritoneal carcinomatosis. Developed by Oncoinvent, the therapy consists of biodegradable calcium carbonate microparticles that act as carriers for the alpha-emitting radionuclide radium-224 (224Ra). Following cytoreductive surgery (with or without hyperthermic intraperitoneal chemotherapy, HIPEC), the microparticles are administered directly into the peritoneal cavity. They distribute throughout the cavity and deliver short-range, high-energy alpha radiation, which induces double-strand DNA breaks in residual microscopic disease and free-floating cancer cells while sparing surrounding healthy tissues. Radspherin is currently being evaluated in Phase 2 clinical trials for peritoneal metastases originating from ovarian and colorectal cancers.
| Indication | Highest phase | Status |
|---|---|---|
| colorectal cancer (CRC) and precursor lesions | In development | Active |
| fallopian-tube cancer and precursor lesions | In development | Active |
| ovarian cancer and premalignant lesions | In development | Active |
| primary peritoneal malignancies | In development | Active |
Every indication, with countries and timelines, is in the full profile.
| Market | Status | Year |
|---|---|---|
| United States | Not approved | — |
| European Union | Not approved | — |
| China | Not approved | — |
| Japan | Not approved | — |
Approved indications and other markets are in the full profile.
Patent families, expiry dates and exclusivities are in the full profile.
Lead indication: colorectal cancer (CRC) and precursor lesions
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on radium-224 calcium carbonate microparticles.
Work on radium-224 calcium carbonate microparticles? Claim this page to correct or add information. Claim this page